Allergan acquires NMDA depression drug from Aptinyx collab by Conor Hale Tuesday, May 22, 2018 Allergan acquired an NMDA receptor modulator discovered by Aptinyx, planning to pair it with its rapastinel depression therapy currently in phase 3.